29 October 2020
Visiongain has published a new report on Bioprocess Validation Market Report : Forecasts by Test Type (Extractables and Leachables, Integrity Testing, Microbiology Testing), Process Component (Filter Element, Bioreactors), End User (Biotechnology & Pharmaceutical Companies). PLUS Profiles of Leading Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Bioprocess Validationmarket was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031.
Validation is a method of building documentary evidence demonstrating a process, activity or procedure, carried out in production or testing maintains the desired level of compliance at all stages. Validation is an action of documenting and demonstrating that any process, procedure, and activity will consistently drive to the required results. It includes the qualifications of equipment and systems.
The global bioprocess validation market is segmented on the basis of process component, test type, end user and geography. The market is segmented into extractable and leachable, integrity testing, microbiology testing. This segment are expected to grow in future.
High demand for outsourcing of bioprocess validation services, stringent safety and quality regulations governing products certifications and testing beyond the biopharmaceutical and pharmaceutical industries in healthcare industry to maintain the agreement with good manufacturing practices are the important factors propelling the growth of this market.
Global bioprocess validation market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships,acquisitions and others to increase their footprints in this market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions and others to increase their footprints in this market. Some companies profiled in the report include- Merck KGaA (Germany) , SGS S.A.(Switzerland),Erofins Scientific(Luxembourg), Sartorius AG (France), Pall Corporation(US), Cobetter FiltrationEquipment co LTD (China),Toxikon corporation (US) , DOC S.R.L (Italy) , Meissner Filtration Products, INC (US), Thermo Fisher Scientific (US)
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.
13 November 2020
Hypertensive is the most common disease around the world. However, number of people suffering from hypertensive has increased very significantly from last few years. Hypertensive can occur due to consumption of tobacco, too much salt (sodium) and little potassium in your diet, alcohol and to people being overweight or obese.
13 November 2020
The prevalence of bacterial diseases is significantly growing and expected to continuously rise over the forecast period. Number of bacterial diseases cases are increasing, like, bugs biting, including ticks, mosquitoes, lice and from an infected animal, contaminated food or water.
13 November 2020
Delivery of biologics through the transdermal route is anticipated to open new avenues for the manufacturers of topical drugs. Transdermal route provides appropriate and painless self-administration for patients. It overcomes frequent dosing administration, plasma level instability related to oral dosing and injections to uphold constant drug concentrations, and a drug with a short half-life can be supplied effortlessly.